Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pioglitazone deuterated - Poxel

Next Previous
Drug Profile

Pioglitazone deuterated - Poxel

Alternative Names: (R)-Pioglitazone deuterated - Poxel; Deuterated pioglitazone; Deuterium stabilised enantiomer pioglitazone; Deuterium-stabilized R-pioglitazone; DRX 065; PXL 065; R-Pioglitazone deuterated - Poxel

Latest Information Update: 22 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DeuteRx
  • Class Anti-inflammatories; Antihyperglycaemics; Hepatoprotectants; Indans; Neuroprotectants; Organic deuterium compounds; Phenyl ethers; Piperidines; Pyridines; Small molecules; Thiazolidinediones
  • Mechanism of Action Mitochondrial membrane transport protein inhibitors; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis
  • Phase I Adrenomyeloneuropathy
  • Preclinical Adrenoleucodystrophy

Most Recent Events

  • 08 Nov 2023 Poxel plans a phase IIa proof-of-concept biomarker trial in Adrenoleukodystrophy with initial focus on adrenomyeloneuropathy in 2023 (NCT05200104)
  • 31 Jul 2023 Poxel has patent protection for Pioglitazone deuterated in the European Union
  • 25 Jan 2023 Pioglitazone deuterated - Poxel receives Orphan Drug status for Adrenoleucodystrophy in European Union
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top